Budesonide

Showing study: Oral Budesonide for Active Crohn's Disease (Greenberg et al.)

Benefits

Risk

Overtime:
SHOW:
grid-1
grid-1

Benefit

Harm

Study overview

  • Figure shows absolute benefit/risk. This is calculated by assessing benefit/risk of study drug against placebo, except where stated
  • Double-blind, multicenter trial of 258 patients with CDAI > 200 were randomly assigned to receive placebo or one of three doses of budesonide (3, 9, or 15 mg daily)
  • Primary outcome measure was clinical remission, as defined by a score of 150 or less on the Crohn's disease activity index
  • The proportion of patients with corticosteroid-associated effects was not significantly different between the groups: 38 percent in the 15-mg group, 26 percent in the 9-mg group, 15 percent in the 3-mg group, and 26 percent in the placebo group

Terms and conditions

By using this site you acknowledge that the content of this website is based on a review process of the ECCO Consensus Guidelines and primarily aims at facilitating their visualization.

Any treatment decisions are a matter for individual clinicians and may not be based primarily on the e-Guide content.

The European Crohn's and Colitis Organisation and/or any of its staff members and/or any website contributor may not be held liable for any information published in good faith on this website.

You agree that the use of this website is at your own risk and hereby waive any and all potential claims against European Crohn's and Colitis Organisation, and/or any of its staff members and/or any of the website contributors.